Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nilvadipine + pioglitazone + telmisartan
- Development stage
- Unknown
- Lead developer
- Archer Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of three medications with different mechanisms of action: nilvadipine (a calcium channel blocker), pioglitazone (a thiazolidinedione antihyperglycemic), and telmisartan (an angiotensin II receptor blocker). This combination is not documented as a specific product but would theoretically target both hypertension and type 2 diabetes.
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)PPARG (Peroxisome proliferator-activated receptor gamma)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on nilvadipine + pioglitazone + telmisartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nilvadipine + pioglitazone + telmisartan.